Autoimmune disorders, rheumatoid arthritis, systemic inflammation, and immune dysregulation
305 articles
New research suggests intramuscular fat infiltration could be a missing piece in understanding how muscle loss accelerates knee osteoarthritis.
Major study shows evolving therapies reduced lung disease progression from 21% to 12% in systemic sclerosis patients over the past decade.
Researchers identify OGFRL1 gene deficiency as a novel cause of chronic bone disease, with promising treatment response to TNF inhibitors.
New clinical insights into treating Rowell syndrome, a rare skin manifestation affecting lupus patients with serious complications.
New research reveals how where you live dramatically affects your ability to receive proper care for psoriatic arthritis.
Revolutionary cell therapy achieves drug-free remission in patients with severe myasthenia gravis, an autoimmune muscle disorder.
Systematic review reveals younger RA patients achieve higher remission rates and better outcomes with biologic therapies than older patients.
Real-world study reveals sarilumab and JAK inhibitors work equally well for rheumatoid arthritis, but sarilumab causes fewer infections.
JAK inhibitors outperform traditional treatments for rheumatoid arthritis but carry cardiovascular and infection risks.
Pfizer's oral JAK inhibitor demonstrated efficacy comparable to adalimumab for treating moderate to severe rheumatoid arthritis.
New research reveals how RA affects muscle biomechanics within 6 months of symptom onset, offering insights for early intervention.
Large Hong Kong registry study tracked how well patients stayed on newer JAK inhibitors versus traditional TNF blockers for RA treatment.
